Senseonics Stock Price, News & Analysis

Senseonics (SENS) will transfer its common stock listing from NYSE American to the Nasdaq Global Select Market, effective after market close on November 14, 2025. The company expects its shares to begin trading on Nasdaq under the existing ticker SENS on November 17, 2025. The move is described as a decision made in the best interest of the company and its stockholders and does not change the company ticker symbol.

Senseonics (NYSE American: SENS) reported third quarter 2025 results with $8.1M revenue, up 90% YoY, driven by a 160% increase in U.S. new patient starts. Q3 gross profit was $3.5M versus a gross loss in Q3 2024. Net loss narrowed to $19.5M ($0.43/share) from $24.0M a year earlier. Management completed a 1-for-20 reverse stock split (approx. 41M shares outstanding) and plans to move listing to Nasdaq Global Market on Nov 17, 2025. Full-year 2025 revenue outlook is ~$35M, with expected 2025 gross margins of 35–40% and ~$60M cash used in operations.

Senseonics (NYSE American: SENS) will release third quarter 2025 financial results after market close on Wednesday, November 5, 2025. Management will host a conference call and concurrent webcast to review Q3 2025 performance starting at 4:30 p.m. Eastern Time the same day.

The webcast link will be posted and archived under Investor Relations > Events & Publications at www.senseonics.com. To join the call, dial 1-800-343-5172 (US/Canada) or 1-203-518-9856 (International) and use passcode SENSQ3, connecting about ten to five minutes before the start time.

Senseonics (NYSE American: SENS) reported preliminary unaudited Q3 2025 revenue of $8.1 million, a 91% increase versus Q3 2024, driven by ~160% new patient growth in the U.S. and record monthly new patient starts in September 2025. The company cited increased direct-to-consumer marketing and bringing sales and marketing in-house as drivers of momentum for its Eversense 365 CGM.

Senseonics also announced a 1-for-20 reverse stock split, reducing issued shares from ~816 million to ~41 million, expected effective at 5:00 p.m. ET on October 17, 2025, with post-split trading beginning October 20, 2025 under symbol SENS.

Senseonics (NYSE:SENS) has signed a memorandum of understanding with Ascensia Diabetes Care to take over commercial operations for Eversense® CGM systems starting January 1, 2026. The agreement aims to unite Eversense's R&D, manufacturing, and commercial activities under Senseonics' control.

The transfer comes after Ascensia's successful launch of Eversense 365, the world's first one-year CGM system, in October 2024. Most of Ascensia's Eversense commercial team, including CGM President Brian Hansen, will transition to Senseonics. The companies expect minimal disruption for business partners, patients, and providers during the transition.

Senseonics (NYSE American: SENS) announced a significant strategic shift in its Eversense 365 commercialization strategy. The company has signed a Memorandum of Understanding to take over all global commercialization and distribution from Ascensia Diabetes Care, effective January 1, 2026.

Key developments include the appointment of Brian Hansen as Chief Commercial Officer and an expanded debt facility up to $100 million with Hercules Capital to fund the commercial organization. The company expects 2025 global net revenue of $34-38 million and projects gross margin expansion to 50% in 2026, increasing to over 70% at scale.

For 2025, Senseonics anticipates doubling its global patient base, with gross margins between 32.5% and 37.5%. Cash used in operations is expected to be approximately $60 million.

Senseonics Holdings (NYSE American: SENS) reported Q2 2025 financial results, achieving $6.6 million in revenue, up 37% year-over-year, driven by a 79% increase in U.S. new patient starts. The company raised $77.8 million in total gross proceeds, including $57.5 million from a public offering and $20.3 million from Abbott.

Q2 net loss improved to $14.5 million ($0.02 per share) from $20.3 million in Q2 2024. The company expanded its DTC advertising campaign, completed provider transition to Eon Care, and entered a commercial agreement to integrate Sequel Med Tech's twiist™ AID system with Eversense 365.

For full-year 2025, Senseonics maintains guidance of $34-38 million in global net revenue, expecting to double its global patient base with gross margins between 32.5% and 37.5%.

Senseonics Holdings (NYSE American: SENS), a medical technology company specializing in long-term implantable continuous glucose monitoring systems for diabetes patients, has scheduled its second quarter 2025 earnings release and conference call for August 6, 2025.

The financial results will be released after market close, followed by a management conference call at 4:30 PM Eastern Time. Investors can access the call via phone (US/Canada: 1-800-225-9448, International: 1-203-518-9708, passcode: SENSQ2) or through a webcast available on the company's investor relations website.

Senseonics Holdings (NYSE: SENS) announced an upcoming analyst event on June 21, 2025, at 8:00am CT at the Marriot Marquis Chicago, coinciding with ADA 2025. The event will showcase their FDA-approved Eversense 365 Continuous Glucose Monitoring system for diabetes patients 18 and older. Key speakers include company management, Brian Hansen from Ascencia Diabetes Care discussing the commercial launch, and Gary Graf from Cotton-O'Neil discussing system experience and insertion procedures. Management will also address their partnership with Sequel for the twiist automated insulin delivery pump integration and future implantable CGM technology developments. The event will be available both in-person and virtually, concluding with a Q&A session.